INTEL CORP (INTC): what the price requires

At today's price, INTEL CORP (INTC) is priced for today's economics sustained for ~11.5 years. boothcheck doesn't publish a fair value or a price target; it shows what the price assumes, so you can judge whether that bar is too high.

Generated: 2026-07-13 · Source: https://boothcheck.com/report/INTC

Headline

FieldValue
TickerINTC
CompanyINTEL CORP
Current price$102.97/sh
CompositionClient Computing Group (CCG) 61% / Data Center and AI (DCAI) 32% / Intel Foundry 34% / All Other 7% / Corporate Unallocated 0% / Intersegment Eliminations -33%

What The Price Requires (Inversion)

The assumption today's price embeds, recovered by inverting the valuation.

FieldValue
Inversion basiswhole-company
Operating margin needed60.4%
Operating margin (mid-cycle)25.3%
Margin expansion implied+35.1pp
Trailing margin (depressed year)-11.2%
Must persist for11.5y
Multiple paid41x mid-cycle operating income

The operating-margin requirement is derived from the framework's value band at year 12, a separately labeled basis from the headline growth/duration solve.

Solve inputs: computed at a 10.8% cost of capital; growth searched up to the 25% self-funding ceiling; each 1pp moves the implied horizon ~2.1 years.

Reconcile: at the x-ray's 9.3% required return this reads ~8.3 years; the models below use their own rates.

How unusual the bet is: elevated

ReferenceValue
vs own history+0.96σ
sustained it ~10 years at this level15%
implied end-window share1%

Valuation X-Ray

Every valuation family lands below the price. The price therefore requires assumptions beyond what those standard frames encode.

How the valuation models price the stock relative to the market price. Price/FV above 1.0 means the market pays more than that lens defends (expensive); at or below 1.0 the lens can defend the price.

FamilyMedian price/FVModelsReads
Asset4.96x2expensive
Earnings0
Relative1.95x2expensive
Growth3.21x2expensive

Families that call it expensive: Asset, Relative, Growth

The models below discount at their own flat-beta convention rates (cost of equity 9.3%, WACC 8.6%); the inversion above states its own rate.

Per-Model Detail (n=6)

ModelFamilyFVPrice/FVApplicableMethodology
DCF Perpetual GrowthGrowth$22.294.62xyesReference only (OCF-based, capex excluded): OCF $10.0B
DCF Exit MultipleGrowth$0.00noNegative/zero FCF or EBITDA — equity value floored at $0
Relative ValuationRelative$52.891.95xyesP/S fallback (negative EPS): Sector P/S 5.0x × TTM revenue — excluded from consensus
Simple DDMGrowthno
Two-Stage DDMGrowthno
Simple Excess ReturnAsset$21.924.70xyesReference only (book value floor): BV/sh $21.92, ROE negative
Two-Stage Excess ReturnAsset$19.725.22xyesReference only (book value with convergence): BV/sh $21.92, ROE converges to ke
Discounted Future Market CapGrowth$57.221.80xyesRev $53.8B, growth 2% (input: historical growth; tapered), Terminal P/S: 6.7x / 8.0x / 9.3x (bear / base = today's held flat / bull, cap 8x)
Peter Lynch Fair ValueRelative$0.00noNegative/zero EPS — earnings-based value floored at $0
Margin TrajectoryGrowthno
Earnings Power ValueEarnings$3.3530.74xyesNormalized EBIT (5y avg op income, one-time charges added back) $4.86B × (1−21%) / WACC 8.6% → EPV (no growth) (excluded from median)
Residual IncomeAssetno
Graham NumberAssetno
EV/EBITDA RelativeRelative$0.0110297.00xyesEBITDA $1.37B × sector EV/EBITDA 16.0x (excluded from median)
FCF YieldEarningsno
SBC-Adj FCF YieldEarningsno
Ben Graham FormulaEarningsno
ROIC-Justified P/BAssetno
P/Sales SectorRelative$52.891.95xyesRevenue $53.76B × sector P/S 5.0x
PEG Fair ValueRelativeno
Earnings YieldEarningsno
Funds From Operations MultipleRelativeno
Clinical Phase NPVGrowthno
MertonAssetno
V5 Mechanicalno

Solvency

FieldValue
Net debt$15.8b
Net debt / NOPAT (after-tax)1.50x
Net debt / operating income (pre-tax)1.18x
Interest coverage12.4x
Share count CAGR (dilution)5.5%
Burning cashno

Leverage and coverage are computed on normalized mid-cycle operating income (mid-cycle margin 25.3%); the trailing year was depressed.

Bullet Takeaways

Bull Case

Semiconductors are the one industry where standard valuation arithmetic breaks down on purpose, and Intel is the extreme case. A chip foundry is a multi-year, multi-tens-of-billions capital project whose payoff is binary: either the process node yields and customers come, or it does not and the spending was a write-off. You cannot value that on trailing margins, because the trailing margins are the cost of building the option, not the result of exercising it. Intel today trades at a price that no backward-looking method supports, because the price is not paying for what Intel earns now. It is paying for what a working American leading-edge foundry would be worth.

The operational evidence is finally moving the right way. Intel Foundry revenue rose to $5.4 billion in the most recent quarter, up 20% sequentially, and its operating loss, still a heavy $2.4 billion, narrowed as yields improved across the Intel 3, 4, and 18A nodes. Management said 18A yields are running ahead of internal expectations and tracking to hit year-end targets by mid-2026, about two quarters ahead of plan, with 18A products already ramping in full-volume production. The Terafab project with Tesla, SpaceX, and xAI is the first major external signal that the next node, 14A, is a production-credible target. These are the exact milestones the bull case needed, arriving on or ahead of schedule.

The scale of the prize is what makes the structure work. Intel still owns the x86 franchise in PCs and servers through its Client Computing and Data Center groups, which throw off the cash that funds the foundry buildout. Bank of America double-upgraded the stock to Buy, lifting its target to $160 on a much larger 2030 chip market. The reframe is that Intel is no longer best understood as a chip designer competing on this year's product. It is a national manufacturing asset whose value depends on a turnaround that, for the first time in years, is hitting its dates.

Bear Case

The bear case is moat erosion, and the moat Intel spent decades building, leading the world in manufacturing process technology, has already been chipped away. The 10-K admits it plainly: delays in developing new process technologies and advanced packaging "have allowed competitors using third-party foundries, such as TSMC, to benefit from" the gap. That is the heart of it. Intel fell behind TSMC on the manufacturing race, and once a foundry loses the lead, customers route their most advanced designs elsewhere, which starves the next node of the volume it needs to pay for itself. The turnaround is an attempt to climb back up a hill Intel used to own.

The price has run far ahead of the evidence. Work backward from today's price and it requires Intel to reach operating margins above 80% sustained for well over a decade, against a business running a negative operating margin today. No family of valuation method reaches the price: asset value, earnings power, peer multiples, and even forward growth all land below it. That is not a stock the conservative methods call mildly expensive. It is a price that, on every standard frame, is a bet beyond what the numbers support, riding on a foundry recovery that has shown early progress but has not yet proven it can generate a profit.

The company's own disclosure names the kill switch. Intel writes that "If we are unable to secure a significant external customer for our Intel 14A node, we may pause or discontinue development of Intel 14A and subsequent next generation leading-edge nodes". Strip away the optimism and that is the bear thesis in the company's own words: the leading-edge roadmap is contingent on winning outside customers who have spent years building their supply chains around TSMC. Intel carries $48.6 billion of gross debt against $32.8 billion of liquid assets, so it has the runway to keep trying, but the debt is real and the foundry consumes cash while the proof is pending. The bull and the bear agree on the facts here; they disagree on whether the external customers show up before patience does.

Valuation

Today's price is not a valuation conclusion; it is a wager on a future business. Invert the price and it implies Intel reaching operating margins above 80% and holding them for more than fourteen years, against a trailing operating margin of negative 9%. Read literally that is impossible for a hardware company; read correctly it means the price is paying for a step-change in what Intel is, not an extrapolation of what it has been. The honest framing is that no standard method gets you here.

That is exactly what the methods show. Asset value, peer multiples, earnings power, and forward growth all land well below the current price, and none of the four families reaches it. The price sits at several times where the asset-based lens values the company and well above the peer-multiple read. When every family says expensive and the price holds anyway, the market is pricing an outcome the standard toolkit cannot frame: a successful foundry turnaround that, if it happens, rewrites the margin structure, and if it does not, leaves the conservative methods looking right. The spread between the price and every method IS the premium, and it is a turnaround premium, not a value gap.

Solvency is the part that bounds the downside without resolving the bet. Intel carries $15.8 billion of net debt and $48.6 billion of gross debt, with interest coverage around 13 times when measured against a mid-cycle operating profit that assumes the business earns its historical margins again. The share count has crept up about 5.5% a year, dilution the turnaround has to clear. The balance sheet is not fragile, but it is not the fortress it once was, and it is being spent down on a capital program whose return is years out and conditional on customers Intel has not yet named. The cleanest read: this is not a stock the financials value at today's price. It is a stock the market values at today's price because of what the financials might become.

Catalysts

The most recent quarter, fiscal first-quarter 2026 ended in late March, was the turning point in sentiment. Revenue rose 7% year over year to $13.6 billion, and the foundry segment posted $5.4 billion of revenue, up 20% sequentially, with its operating loss of $2.4 billion improving slightly as yields climbed across the Intel 3, 4, and 18A nodes. The stock has surged dramatically in 2026 on this run of milestones, and analysts now look for a sharp earnings recovery this fiscal year.

The process roadmap carries the near-term catalysts. Management confirmed 18A yields are tracking to hit year-end targets by mid-2026, roughly two quarters ahead of plan, with 18A products already in full-volume production and external design commitments expected to begin in the second half of 2026. The Terafab partnership with Tesla, SpaceX, and xAI was announced alongside the quarter as the first major external validation of the 14A node.

Sentiment shifted hard on the analyst side as well. Bank of America double-upgraded Intel to Buy and raised its price target to $160, citing a much larger projected 2030 chip market. The watch item management itself flagged is gross-margin pressure in the second half of 2026, as rising substrate, memory, and component costs could offset the yield gains; the second-half prints are where the turnaround either consolidates or stalls.

Peer Cohorts (Per Segment, With Filing Citations)

Client Computing Group (CCG) / Data Center and AI (DCAI) / Intel Foundry (reported)

Methodology Note

Fundamentals sourced from SEC EDGAR filings. Current price from Databento. The priced-in inversion and valuation x-ray are computed by the boothcheck engine; narrative composed by AI from the structured data.

Sources

Intel Q1 FY2026 earnings release · Intel Q1 FY2026 earnings call · BofA research note, June 2026 · analyst consensus cited by The Globe and Mail, 2026

View the full interactive INTC report on boothcheck